Evidence map›Paper›PMID 40083540›Full record

ReviewThe Journal of clinical and aesthetic dermatology

Beyond Skin Deep: The Systemic Impact of Topical Corticosteroids in Dermatology.

Douglas DiRuggiero, Margaret DiRuggiero

Abstract readReview
In one paragraph

Review in The Journal of clinical and aesthetic dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Frontiers in pharmacology · 2025
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Douglas DiRuggieroDr. DiRuggiero is with the Skin Cancer and Cosmetic Dermatology Center in Rome, Georgia.
Margaret DiRuggieroMs. DiRuggiero is with Emory University School of Medicine in Atlanta, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corticosteroids are widely prescribed for a variety of dermatologic indications. However, since 2020, regulatory bodies from Canada and the United Kingdom, as well as academic and patient advocacy societies, are increasingly calling for limiting topical corticosteroid use due to safety concerns. This article reviews the variety and extent of both cutaneous adverse effects (i.e., steroid-induced damage) and systemic adverse effects from topical corticosteroids and explores alternative therapies. The risk of adverse effects increases with steroid potency, amount, duration, and frequency of use across indications, routes of administration, and prescribers (i.e., cumulative steroid dose). In order to reduce these safety risks, clinicians should prescribe steroids appropriately and counsel patients on appropriate use and consider combination topical corticosteroid therapy or newer alternative steroid-sparing treatments.

Indexed as

cutaneous adverse effectssteroid-induced damagesystemic adverse effectsTopical corticosteroidstopical steroid withdrawal syndrome

Identifiers

PMID40083540
PMCPMC11903052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.